Seegene Launches Allplex™ MDRO Assay in Europe to Combat Antimicrobial Resistance
Seegene, a prominent player in the field of molecular diagnostics, has unveiled its newest product, the Allplex™ MDRO Assay, aimed at responding to the growing challenge of antimicrobial resistance (AMR) in Europe. This launch is not only a testament to Seegene's commitment to addressing health challenges but also a strategic step to bolster the diagnosis and management of healthcare-associated infections (HAIs).
The Allplex™ MDRO Assay is designed to enhance the detection capabilities of multidrug-resistant organisms (MDROs) that are prevalent in healthcare settings. It is CE marked under the EU In Vitro Diagnostic Regulation (IVDR), ensuring that it meets rigorous standards for safety and efficacy. With the rise in antimicrobial resistance rates, the need for rapid and accurate testing has never been more critical. The assay is particularly important as it supports rapid first-line screening for MDROs, facilitating timely responses to infection prevention and control in hospitals.
One of the significant features of the Allplex™ MDRO Assay is its ability to identify multiple key MDRO pathogens and their associated resistance genes within a single testing cycle. This simultaneous detection across a broader spectrum of MDRO targets allows for enhanced diagnostic accuracy, which is crucial for effective infection control measures. The assay can offer same-day reporting in line with laboratory workflows, thereby providing healthcare professionals with immediate insights to inform their clinical decisions.
As public health entities, including the U.S. Centers for Disease Control and Prevention (CDC), emphasize the necessity for improved infection surveillance and control capabilities, Seegene’s initiative to expand its AMR testing portfolio appears timely. This product extends Seegene’s existing testing offerings, which includes the Allplex™ Entero-DR Assay, creating a robust combined testing strategy against antimicrobial-resistant organisms.
Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene, expressed enthusiasm for the launch, indicating that it represents a considerable step towards expanding their portfolio and enhancing hospital infection control efforts. The company's commitment to advancing diagnostic technologies is underscored by plans to develop additional assays, including the upcoming Allplex™ MRSA Assay focused on the detection of methicillin-resistant Staphylococcus aureus (MRSA).
The introduction of the Allplex™ MDRO Assay responds directly to the global rise in antimicrobial resistance and the surging incidence of healthcare-associated infections. These issues have exacerbated the challenge for healthcare providers in managing treatment protocols and infection control practices.
Seegene has built its reputation over 25 years as a global leader in molecular diagnostics, leveraging proprietary multiplex PCR technology that allows for the detection of multiple pathogens in one test. This innovation not only aids in more efficient clinical decision-making but also enhances patient outcomes by facilitating timely treatment.
In addition to the Allplex™ MDRO Assay, Seegene is continuously evolving its technologies to create an integrated diagnostic ecosystem. This includes initiatives like STAgora™, a real-time diagnostic data analytics platform, and CURECA™, a fully automated PCR system, both of which aim to streamline molecular testing workflows and broaden access to these essential diagnostics.
In conclusion, the launch of the Allplex™ MDRO Assay signifies Seegene's proactive approach to combatting antimicrobial resistance and improving infection control practices in healthcare settings. As the demand for effective diagnostic solutions grows, Seegene is positioned at the forefront of this critical healthcare movement, focusing on delivering innovative technologies to enhance patient safety and care standards worldwide.
The Allplex™ MDRO Assay is designed to enhance the detection capabilities of multidrug-resistant organisms (MDROs) that are prevalent in healthcare settings. It is CE marked under the EU In Vitro Diagnostic Regulation (IVDR), ensuring that it meets rigorous standards for safety and efficacy. With the rise in antimicrobial resistance rates, the need for rapid and accurate testing has never been more critical. The assay is particularly important as it supports rapid first-line screening for MDROs, facilitating timely responses to infection prevention and control in hospitals.
One of the significant features of the Allplex™ MDRO Assay is its ability to identify multiple key MDRO pathogens and their associated resistance genes within a single testing cycle. This simultaneous detection across a broader spectrum of MDRO targets allows for enhanced diagnostic accuracy, which is crucial for effective infection control measures. The assay can offer same-day reporting in line with laboratory workflows, thereby providing healthcare professionals with immediate insights to inform their clinical decisions.
As public health entities, including the U.S. Centers for Disease Control and Prevention (CDC), emphasize the necessity for improved infection surveillance and control capabilities, Seegene’s initiative to expand its AMR testing portfolio appears timely. This product extends Seegene’s existing testing offerings, which includes the Allplex™ Entero-DR Assay, creating a robust combined testing strategy against antimicrobial-resistant organisms.
Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene, expressed enthusiasm for the launch, indicating that it represents a considerable step towards expanding their portfolio and enhancing hospital infection control efforts. The company's commitment to advancing diagnostic technologies is underscored by plans to develop additional assays, including the upcoming Allplex™ MRSA Assay focused on the detection of methicillin-resistant Staphylococcus aureus (MRSA).
The introduction of the Allplex™ MDRO Assay responds directly to the global rise in antimicrobial resistance and the surging incidence of healthcare-associated infections. These issues have exacerbated the challenge for healthcare providers in managing treatment protocols and infection control practices.
Seegene has built its reputation over 25 years as a global leader in molecular diagnostics, leveraging proprietary multiplex PCR technology that allows for the detection of multiple pathogens in one test. This innovation not only aids in more efficient clinical decision-making but also enhances patient outcomes by facilitating timely treatment.
In addition to the Allplex™ MDRO Assay, Seegene is continuously evolving its technologies to create an integrated diagnostic ecosystem. This includes initiatives like STAgora™, a real-time diagnostic data analytics platform, and CURECA™, a fully automated PCR system, both of which aim to streamline molecular testing workflows and broaden access to these essential diagnostics.
In conclusion, the launch of the Allplex™ MDRO Assay signifies Seegene's proactive approach to combatting antimicrobial resistance and improving infection control practices in healthcare settings. As the demand for effective diagnostic solutions grows, Seegene is positioned at the forefront of this critical healthcare movement, focusing on delivering innovative technologies to enhance patient safety and care standards worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.